drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous gene-modified T-cell therapy)
drug_description
Autologous peripheral blood lymphocytes genetically engineered to express T-cell receptors specific for KRAS G12D or G12V neoantigens (HLA class I/II–restricted) to recognize mutant KRAS peptides and kill tumor cells.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_category
ENGINEERED TCR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are genetically engineered to express HLA class I/II-restricted T-cell receptors specific for KRAS G12D or G12V neoantigen peptides; binding of these mutant KRAS peptides on tumor cells triggers T-cell activation and cytotoxic killing (perforin/granzyme-mediated lysis) of the target cells.
drug_name
KRAS TCR-Transduced PBL
nct_id_drug_ref
NCT06253520